EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to ...
Population aging is reshaping the landscape of respiratory disease, with COPD, idiopathic pulmonary fibrosis, bronchiectasis, ...
Although there is significant improvement in managing asthma and chronic obstructive pulmonary disease (COPD) diseases, there is still a strong need in controlling symptoms to prevent hospitalizations ...
Chronic obstructive pulmonary disease – COPD for short – is one of the most common diseases of the lung. It affects almost 300 million people worldwide, of which about three million die every year. A ...
Forbes contributors publish independent expert analyses and insights. I cover end-of-life care and dabble in the culture of medicine. Results from a new report published in the British Journal of ...
REYKJAVIK, Iceland, June 11, 2025--(BUSINESS WIRE)--EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory ...
EpiEndo Pharmaceuticals ('EpiEndo' or the 'Company'), a clinical-stage biopharmaceutical company developing a new class of oral anti-inflammatory drugs which enhance the host defence response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results